Published online before print October 11, 2004, doi: 10.1161/01.CIR.0000145166.44942.E0
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:2342-2348.)
© 2004 American Heart Association, Inc.
Coronary Heart Disease |
Cystatin C
A Novel Predictor of Outcome in Suspected or Confirmed Non–ST-Elevation Acute Coronary Syndrome
From the Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center (T.J., B.L., S.J., L.W.), and Department of Medical Sciences, Clinical Chemistry, University Hospital (A.L., L.-O.H.), Uppsala, Sweden.
Correspondence to Tomas Jernberg, MD, PhD, Department of Medical Sciences, Cardiology, Uppsala Research Center, University Hospital, 751 85 Uppsala, Sweden. E-mail tomas.jernberg{at}medsci.uu.se
Received March 28, 2004; revision received June 15, 2004; accepted June 18, 2004.
Background— Patients with suspected or confirmed non–ST-elevation acute coronary syndrome (ACS) constitute a large and heterogeneous group. Measurements of renal function such as serum creatinine and estimation of creatinine clearance carry independent prognostic information in this population. Cystatin C is a new and better marker of renal function than creatinine. The aim was therefore to evaluate the prognostic value of cystatin C in this population.
Methods and Results— Cystatin C was analyzed on admission in 726 patients admitted because of symptoms suggestive of an acute coronary syndrome and no ST-segment elevations. Patients were followed up with regard to death and myocardial infarction for a median of 40 and 6 months, respectively. The median cystatin C level was 1.00 mg/L (25th to 75th percentile, 0.83 to 1.24 mg/L). The risk of death during follow-up increased with increasing levels of cystatin C. In the group with non–ST-elevation ACS, patients in the second, third, and fourth quartiles had a relative risk of subsequent death of 1.8 (95% CI, 0.6 to 5.3), 3.2 (95% CI, 1.2 to 8.5), and 11.7 (95% CI, 4.7 to 29.3) compared with the lowest quartile. In Cox regression models including well-known predictors of outcome, cystatin C level was independently associated with mortality but not with the risk of subsequent myocardial infarction. In a comparison of the markers of renal function in receiver-operating curve analyses, cystatin C had the best ability to discriminate between survivors and nonsurvivors.
Conclusions— A single measurement of cystatin C will substantially improve the early risk stratification of patients with suspected or confirmed non–ST-elevation ACS.
Key Words: angina • cystatins • kidney • myocardial infarction • prognosis
This article has been cited by other articles:
 |
|
 |
|
  K. A.A. Fox, J.-P. Bassand, S. R. Mehta, L. Wallentin, P. Theroux, L. S. Piegas, V. Valentin, T. Moccetti, S. Chrolavicius, R. Afzal, et al. Influence of Renal Function on the Efficacy and Safety of Fondaparinux Relative to Enoxaparin in Non ST-Segment Elevation Acute Coronary Syndromes Ann Intern Med, September 4, 2007; 147(5): 304 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. MacGregor How common is early chronic kidney disease?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_9): ix8 - ix18. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lassus, V.-P. Harjola, R. Sund, K. Siirila-Waris, J. Melin, K. Peuhkurinen, K. Pulkki, M. S. Nieminen, and for the FINN-AKVA Study group Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP Eur. Heart J., August 1, 2007; 28(15): 1841 - 1847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ledoux, M. Monchi, J.-P. Chapelle, and P. Damas Cystatin C blood level as a risk factor for death after heart surgery Eur. Heart J., August 1, 2007; 28(15): 1848 - 1853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Menon, M. G. Shlipak, X. Wang, J. Coresh, T. Greene, L. Stevens, J. W. Kusek, G. J. Beck, A. J. Collins, A. S. Levey, et al. Cystatin C as a Risk Factor for Outcomes in Chronic Kidney Disease Ann Intern Med, July 3, 2007; 147(1): 19 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Ix, M. G. Shlipak, G. M. Chertow, and M. A. Whooley Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease: Data From the Heart and Soul Study Circulation, January 16, 2007; 115(2): 173 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Jaffe, L. Babuin, and F. S. Apple Biomarkers in Acute Cardiac Disease: The Present and the Future J. Am. Coll. Cardiol., July 4, 2006; 48(1): 1 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koenig, D. Twardella, H. Brenner, and D. Rothenbacher Lipoprotein-Associated Phospholipase A2 Predicts Future Cardiovascular Events in Patients With Coronary Heart Disease Independently of Traditional Risk Factors, Markers of Inflammation, Renal Function, and Hemodynamic Stress Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1586 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Westhuyzen Cystatin C: a Promising Marker and Predictor of Impaired Renal Function Ann. Clin. Lab. Sci., January 1, 2006; 36(4): 387 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Shlipak, C. L. W. Fyr, G. M. Chertow, T. B. Harris, S. B. Kritchevsky, F. A. Tylavsky, S. Satterfield, S. R. Cummings, A. B. Newman, and L. F. Fried Cystatin C and Mortality Risk in the Elderly: The Health, Aging, and Body Composition Study J. Am. Soc. Nephrol., January 1, 2006; 17(1): 254 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald The Year in Non--ST-Segment Elevation Acute Coronary Syndromes J. Am. Coll. Cardiol., September 6, 2005; 46(5): 906 - 919. [Full Text] [PDF]
|
|
|
|
|
|
M. Loew, M. M. Hoffmann, W. Koenig, H. Brenner, and D. Rothenbacher Genotype and Plasma Concentration of Cystatin C in Patients With Coronary Heart Disease and Risk for Secondary Cardiovascular Events Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1470 - 1474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Kirtane, D. M. Leder, S. S. Waikar, G. M. Chertow, K. K. Ray, D. S. Pinto, D. Karmpaliotis, A. J. Burger, S. A. Murphy, C. P. Cannon, et al. Serum Blood Urea Nitrogen as an Independent Marker of Subsequent Mortality Among Patients With Acute Coronary Syndromes and Normal to Mildly Reduced Glomerular Filtration Rates J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1781 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Levin Cystatin C, Serum Creatinine, and Estimates of Kidney Function: Searching for Better Measures of Kidney Function and Cardiovascular Risk Ann Intern Med, April 5, 2005; 142(7): 586 - 588. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Curhan Cystatin C: A Marker of Renal Function or Something More? Clin. Chem., February 1, 2005; 51(2): 293 - 294. [Full Text] [PDF]
|
|